Real-time attendance alert system integrating ZK BioTime CSV exports with Telegram notifications. Designed for on-premise environments where HR/IT need instant visibility without manual checks.

BioTime will report earnings from Q4 on March 7. Analysts predict BioTime will release losses per share of $0.043. Go here to track BioTime stock price in real-time on Markets Insider. BioTime ...

BIOTIME PHARMACEUTICALS PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the ...

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer ...

BIOTIME HEALTHCARE PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the ...

Please provide your email address to receive an email when new articles are posted on . BioTime has changed its name to Lineage Cell Therapeutics to better reflect its commitment to becoming a leading ...

Please provide your email address to receive an email when new articles are posted on . The first patient has been dosed in an ongoing phase 1/2a clinical trial with a new thaw-and-inject formulation ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of ...

BioTime has received US$43 million (€37 million) from Juvenescence for a stake in AgeX and plans to spin the cell therapy subsidiary out in September. In April 2017, Californian late-stage biotech ...

BioTime to receive $21.6 million in cash and $21.6 million in a convertible/redeemable note for 14.4 million shares of AgeX Therapeutics ALAMEDA, Calif.--(BUSINESS ...